Abstract
Primary biliary cirrhosis (PBC) is occasionally developed in patients with rheumatic diseases, such as systemic sclerosis or Sjogren's syndrome. However, there are a few reports of overlap syndrome with PBC. The authors report a case of a 36 year-old female with PBC and overlap syndrome. Systemic sclerosis was diagnosed in 2007, and rheumatoid arthritis in 2010. Adalimumab stopped because of her pregnancy plan in January 2012. One month after delivery, she felt increased hand joint pain and fatigue. Laboratory findings were as follows: elevated AST, ALT, ALP, r-GTP and positive anti-mitochondrial antibody. Histology of a liver biopsy revealed moderate porto-periportal and mild lobular inflammation with bile duct inflammation, which was consistent with PBC. She was treated with prednisolone and UDCA (urosodeoxycholic acid), but her disease was not controlled. From May 2013, she has been treated with adalimumab. Her arthritis was improved and liver function test normalized up until now.
REFERENCES
2. Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004; 97:397–406.
3. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009; 36:2250–6.
4. Maekawa S, Yano E, Shintani S. A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies. Ryumachi. 1992; 32:515–21.
5. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Enhanced expression of TNFa in patients with primary biliary cirrhosis. Int Hepatol Commun. 1994; 2:6–13.
6. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol. 2002; 17:196–202.
7. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med. 1973; 289:674–8.
8. Polido-Pereira J, Rodrigues AM, Canhão H, Saraiva F, da Silva JA, Fonseca JE. Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review. Clin Rheumatol. 2012; 31:385–9.
9. Spadaro A, Scrivo R, Riccieri V, Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine. 2008; 75:87–9.
10. Ogata A, Terabe F, Nakanishi K, Kawai M, Kuwahara Y, Hirano T, et al. Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint Bone Spine. 2009; 76:105–7.
11. Kubo S, Iwata S, Saito K, Tanaka Y. Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine. 2011; 78:535–6.
12. Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis. 1982; 41:612–4.
13. Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013; 37:572–85.
14. Gupta RC, Seibold JR, Krishnan MR, Steigerwald JC. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin Exp Immunol. 1984; 58:68–76.